X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AnQlar (quaternary ammonium palmitoyl glycol chitosan) is a nanoparticle intended to prevent the spread of negatively charged viruse such as COVID-19 and influenza via intranasal spray, and has shown to inhibit the ability of the virus to replicate at non-toxic concentrations.
Lead Product(s): Quaternary Ammonium Palmitoyl Glycol Chitosan
Therapeutic Area: Infections and Infectious Diseases Product Name: AnQlar
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Virpax Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
AL001, is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, for the treatment of dementia related to AD, bipolar disorder, MDD, and PTSD.
Lead Product(s): Lithium Salicylate Proline
Therapeutic Area: Neurology Product Name: AL001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Altasciences Company Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: HT-TBI
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Hoth Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 20, 2022
Details:
Alladapt in their important goal of developing a single therapeutic ADP101, to address a wide range of mono- and multi-food allergies, and looking forward to fulfilling their Phase III and commercial requirements.
Lead Product(s): ADP101
Therapeutic Area: Immunology Product Name: ADP101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alladapt Immunotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 15, 2022
Details:
Under the agreement, Altasciences and iResearch will manage and conduct, Alzamed's Phase IIA study evaluating AL001, a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, for Alzheimer’s Disease.
Lead Product(s): Lithium Salicylate Proline
Therapeutic Area: Neurology Product Name: AL001
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Alzamend Neuro
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 11, 2022
Details:
Epoladerm (diclofenac epolamine) first-in-human study will be conducted in Q2 2022 and is supplied in a pre-filled device for administration as a topical spray film for treatment of chronic pain associated with osteoarthritis of the knee.
Lead Product(s): Diclofenac Epolamine
Therapeutic Area: Musculoskeletal Product Name: Epoladerm
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Virpax Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2022
Details:
Company to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRx-008
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Xortx Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
Under the agreement, Altasciences will conduct a six-month Phase I relative bioavailability study for AL001, a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, for dementia related to Alzheimer’s disease.
Lead Product(s): Lithium Salicylate Proline
Therapeutic Area: Neurology Product Name: AL001
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Alzamend Neuro
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 17, 2021
Details:
As part of the ReAlta ALI program underway, the Phase I trial is a single-ascending dose, randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK, and PD of RLS-0071 in healthy subjects.
Lead Product(s): RLS-0071
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RLS-0071
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
Vibegron is a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults.
Lead Product(s): Vibegron
Therapeutic Area: Urology Product Name: Gemtesa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
